Industry News
Biotechnology Industry News

Following a string of clinical…
Following a string of clinical setbacks, Vistagen’s nasal spray for social anxiety has now failed to top placebo even when given as a double dose. But just like with prior disappointing readouts, the biotech has
Tarsus Pharmaceuticals is fronting…
Tarsus Pharmaceuticals is fronting $450 million to acquire Alkeus Pharmaceuticals for its phase 3-stage retinal disease therapy that's being touted as a potential blockbuster.
BioVie has hailed phase 2 data as…
BioVie has hailed phase 2 data as evidence that bezisterim could represent a “meaningful advance” in the treatment of Parkinson’s disease. But the biotech focused on a new composite measure, rather than its stated primary
Context Therapeutics has stopped…
Context Therapeutics has stopped development of the bispecific T-cell engager CT-95, freeing up cash to extend its runway beyond readouts on its two priority clinical programs.
Actimed Therapeutics has brought…
Actimed Therapeutics has brought the full rights to its wasting disease drug back in house, securing “strategic control” over the asset but losing out on a shot at over $120 million in biobucks.
Braveheart Bio has overcome its…
Braveheart Bio has overcome its own IPO expectations, rallying $382.5 million in an upsized listing to fund its cardiovascular ambitions.
A little over a year ago, LifeMine…
A little over a year ago, LifeMine Therapeutics laid off staff and put its fungus-based platform on ice to focus its dwindling resources on its lead asset. Now, the Massachusetts biotech is shaking off the
Sanofi halted a phase 2 trial…
Sanofi halted a phase 2 trial testing a monoclonal antibody, SAR445399, in non-cystic fibrosis bronchiectasis, Fierce has learned.
Novo Nordisk CFO Karsten Munk…
Novo Nordisk CFO Karsten Munk Knudsen spoke to Fierce the morning the company unveiled its second-quarter earnings, reflecting on Novo’s “roller coaster” financial journey, the pressure of navigating its shifting fortunes and why he remains
Eli Lilly has axed another trial…
Eli Lilly has axed another trial of a gene therapy acquired in its $1 billion Prevail Therapeutics buyout, further denting the drugmaker’s chances of delivering a return on its investment.
Novo Nordisk’s CEO admitted the…
Novo Nordisk’s CEO admitted the Danish pharma has had “a couple of setbacks” in the wake of mixed data for CagriSema and its cardiovascular hopeful ziltivekimab, while stressing that the company is already on the
Attovia Therapeutics has accreted…
Attovia Therapeutics has accreted a hefty $289 million from its IPO to power its anti-itch drugs through clinical development, marking another upsized listing in what has become a banner year for biotech Nasdaq debuts.
Amgen has ended development of its…
Amgen has ended development of its early-stage obesity drug AMG 513, foisting its hopes for a slice of the massive weight loss market onto the shoulders of phase 3 candidate MariTide.
Expedition Therapeutics has…
Expedition Therapeutics has secured an oversubscribed $115 million series B financing from a line-up of big-name investors to propel its lead DPP1 inhibitor through phase 2.
Lisata is laying off 72% of its…
Lisata is laying off 72% of its workforce, including its chief medical officer, as the solid tumor biotech tries to navigate a new future after a planned merger with cancer imaging company Kuva Labs fell
Pfizer has axed two clinical-stage…
Pfizer has axed two clinical-stage obesity programs, dropping a GLP-1 receptor agonist from the Metsera buyout and a GIPR antagonist as part of its quarterly pipeline cleanout.
Latigo Biotherapeutics has fleshed…
Latigo Biotherapeutics has fleshed out its plans for an IPO to finance the development of its clinical-stage pipeline of non-opioid pain management drugs.
A phase 2 trial of Merck &…
A phase 2 trial of Merck & Co.’s anti-TL1A monoclonal antibody has missed its primary endpoint, closing off one avenue for expansion of an asset acquired in a $10.8 billion takeover. The setback was offset
Pathos AI has agreed to pay $125…
Pathos AI has agreed to pay $125 million for a bispecific antibody-drug conjugate from China’s Alphamab Oncology, while adding a Big Pharma partner in the form of AstraZeneca.
BlossomHill Therapeutics plans to…
BlossomHill Therapeutics plans to raise $111.7 million to fund the clinical journey of its potential challenger to Tagrisso.

